ABCG2 and cancer: Therefore, we first examined the cytotoxicity of erdafitinib in multiple human multidrug-resistant cancer cell lines that overexpress ABCB1 or ABCG2 as well as in the corresponding drug-sensitive parental cancer cell lines.